News page specific

Emerging Startups 2021: Top Life Sciences Platforms and Tools Startups

The Life Sciences Platforms and Tools has over 3.6K+ startups that comprise of companies which developing instruments, consumables; and providing services to Life Science companies and academic institutions to enable Life Science R&D.; This includes companies developing Instruments, Lab Automation Devices, Reagents and Kits, Assay Platforms and providing Research Services.

Life Sciences Platforms and Tools is one of the most active sectors for investors, with an overall funding of USD 72.5B in 3.9K+ companies. It is also interesting to note that more than one third of the funding has been raised in the last 3 years (2018-2020).

NIH, JLABS, BIRAC, National Science Foundation and Mass Challenge are amongst the most active investors in this sector, by number of investments.

Research services, nucleic acid sequencing, proteomics, animal models and protein microfluidics are some of the top business models attracting major funding.

We, at Tracxn, keep a track of the latest happenings in the world of startups and their associated ecosystems – including venture capital funds, private equity funds and investment banks amongst others.

In this edition, we have the ‘Life Sciences Platforms and Tools startups 2021’ – a curated list of the most promising startups leading the Life Sciences Platforms and Tools industry, from across the globe.

 

UNICORNS
Unicorns, with their valuations exceeding the billion dollar mark, and even multi-billion mark in a few cases, represent the top Life Sciences Platforms and Tools startups globally.
 
Indigo
 

SOONICORNS
The Soonicorns - soon to be Unicorns - are the handful of highly valued startups which have successfully grown out of their nascency to attract valuations of over a few hundred millions. Watch out for these companies in the coming years as they take on the journey to becoming the elite Unicorns.
 
Human Longevity, Vividion Therapeutics, Tessera Therapeutics, SQZBiotech, EdiGene, KSQ, Vineti, MedGenome, Univercells, Cytek Biosciences, Dewpoint Therapeutics, Emulate, AlloVir, Geltor, HiFiBiO, DNA Script, Korro Bio, LUMICKS, MOMA Therapeutics, Concentric Analgesic, ArsenalBio, Xingeyuan Biotechnology, Alchemab, Clear Labs, Immunai, Glympse Bio, Lyndra, Aspen Neuroscience, Nautilus Biotechnology, Mammoth, Healx, Life Biosciences, Fronteir Medicines, Phoremost, MycoWorks, MOBILion Systems, Checkerspot, NuProbe, Bit bio, Trace Genomics
 

MINICORNS
The Minicorns - are the high growth early stage ventures (Series A+). Watch out for these companies as they take the business to the next level, by scaling up for the accelerated growth.
 
ReCode Therapeutics, Japser Therapeutics, Miroculus, Skyhawk Therapeutics, CorneaGen, Evonetix, Molecular Assemblies, OpenTrons, Fluidic Analytics, Medisix Therapeutics, ArunA Bio, TearClear, Aspect Biosystems, BRAINBox Solutions, Mimetas, Culture Biosciences, Eligo Bioscience, ARTMS, Immunicom, Cardea Bio, TARA Biosystems, Syndesi, Versantis, Catalog Technologies, Magnetic Insight, Cellino Biotech, Bionaut Labs, 54gene, Phylos Bioscience, Ionpath, NanoView Biosciences, twoXAR, PathogenDX, Bioskryb
 
 

DETAILED LIST

Indigo
2013 , Boston (United States)
Provider of microbial technology for plant protection
Investors: Pac-West Telecomm, THRIVE + 16 more
Last round: USD 360M, Series F, Jun 2020
Disclosed Funding USD 1.09B


Human Longevity
2013 , San Diego (United States)
Provider of genomics and cell therapy-based diagnostic and therapeutic company
Investors: GE Ventures, Oceanpine Capital + 13 more
Last round: USD 30M, Series B, Jul 2019
Disclosed Funding USD 330M


Vividion Therapeutics
2016 , Oceanside (United States)
Developing novel drugs based on a proteome-wide ligand and target discovery platform
Investors: BVF Partners, Alexandria + 19 more
Last round: USD 135M, Series C, Feb 2021
Disclosed Funding USD 271M


Tessera Therapeutics
2018 , Cambridge (United States)
Provider of new genome engineering technology for treating multiple diseases
Investors: Flagship Pioneering, Altitude Life Science Ventures + 4 more
Last round: USD 230M, Series B, Jan 2021
Disclosed Funding USD 230M


SQZBiotech
2013 , Boston (United States)
Developer of a platform for the intracellular delivery of macromolecules
Investors: 20/20 HealthCare Partners, Center for Advancement of Science in Space + 23 more
Last round: USD 66M, Series D, May 2020
Disclosed Funding USD 168M


EdiGene
2015 , Changping (China)
Developer of genome editing technology for the treatment of cancer and genetic disease
Investors: Lilly Asia Ventures, Oceanpine Capital + 17 more
Last round: USD 62M, Series B, Apr 2021
Disclosed Funding USD 165M
 

KSQ
2015 , Cambridge (United States)
Drug discovery company employing functional genomics technology
Investors: Alexandria, Flagship Pioneering + 6 more
Last round: USD 81M, Series C, Sep 2018
Disclosed Funding USD 157M
 

Vineti
2016 , San Francisco (United States)
Developer of software for the discovery of personalised medicine
Investors: Lifeforce Capital, McKesson + 15 more
Last round: USD 68M, Series C, Oct 2020
Disclosed Funding USD 151M
 

MedGenome
2013 , Bangalore (India)
Provider of research and clinical genomics solutions
Investors: Tim McLaughlin, ATEL Capital Group + 20 more
Last round: USD 55M, Series D, Apr 2020
Disclosed Funding USD 151M
 

Univercells
2013 , Gosselies (Belgium)
Provider of biomanufacturing technology services for biopharma sector
Investors: Bill & Melinda Gates Foundation, Farallon Capital Management + 13 more
Last round: USD 85M, Series C, Dec 2020
Disclosed Funding USD 146M
 

Cytek Biosciences
2014 , San Francisco (United States)
Manufacturer of flow cytometry systems for research applications
Investors: RA Capital Management, Orbimed + 7 more
Last round: USD 120M, Series D, Nov 2020
Disclosed Funding USD 144M
 

Dewpoint Therapeutics
2018 , Boston (United States)
Developer of small molecule based therapeutics
Investors: Alexandria, Bayer + 9 more
Last round: USD 77M, Series B, Sep 2020
Disclosed Funding USD 137M
 

Emulate
2014 , Cambridge (United States)
Organ on a chip platform that emulates human biology to understand how diseases, medicines, chemicals, and foods affect human health
Investors: Stray Dog Capital, ATEL Capital Group + 18 more
Last round: USD 19M, Conventional Debt, Mar 2020
Disclosed Funding USD 122M
 

AlloVir
2013 , Houston (United States)
Developer of multi-virus specific T-cell therapies
Investors: Samsara, The Invus Group + 6 more
Last round: USD 121M, Series B, May 2019
Disclosed Funding USD 121M
 

Geltor
2015 , San Leandro (United States)
Biodesign company producing advance designer proteins
Investors: adm ventures, Baruch Future Ventures + 29 more
Last round: USD 91M, Series B, Jul 2020
Disclosed Funding USD 116M
 

HiFiBiO
2013 , Paris (France)
Provider of a technology platform for the discovery of antibody-based drugs
Investors: Nest Bio Ventures, Proxima Ventures + 10 more
Last round: USD 67M, Series C, Aug 2019
Disclosed Funding USD 105M
 

DNA Script
2014 , Paris (France)
Developer of benchtop DNA printer for nucleic acid synthesis
Investors: Danaher, Life Sciences Partners + 11 more
Last round: USD 50M, Series B, Jul 2020
Disclosed Funding USD 102M
 

Korro Bio
2018 , Cambridge (United States)
Developer of precision genetic medicine products
Investors: Qiming, Atlas Venture + 5 more
Last round: USD 92M, Series A, Sep 2020
Disclosed Funding USD 96M
 

LUMICKS
2014 , Amsterdam (Netherlands)
Manufactures optical tweezers for single molecule analysis instruments
Investors: Lauxera, Irving Investors + 7 more
Last round: USD 93M, Series D, Apr 2021
Disclosed Funding USD 93M
 

MOMA Therapeutics
2020 , Cambridge (United States)
Developer of therapeutics targeting molecular machines that underlie disease
Investors: Casdin Capital, Rock Springs Capital + 2 more
Last round: USD 86M, Series A, Apr 2020

Disclosed Funding USD 86M


Concentric Analgesic
2014 , San Francisco (United States)
Developer of platform for developing pro-drugs
Investors: Venrock, Cowen + 3 more
Last round: USD 77M, Series B, May 2019

Disclosed Funding USD 85M


ArsenalBio
2019 , San Francisco (United States)
Developer of immune cell therapies
Investors: Westlake Village Biopartners, Kleiner Perkins + 5 more
Last round: USD 85M, Series A, Oct 2019

Disclosed Funding USD 85M


Xingeyuan Biotechnology
2018 , Nanjing (China)
Developer of a platform for single-cell transcriptome analysis for drug discovery
Investors: Tencent, Lilly Asia Ventures + 7 more
Last round: USD 30M, Series A, Dec 2020

Disclosed Funding USD 84M


Alchemab
2019 , London (United Kingdom)
Developer of antibodies to treat cancers, neurodegenerative conditions and infectious diseases
Investors: SV Health Investors, RA Capital Management + 5 more
Last round: USD 83M, Series A, Apr 2021

Disclosed Funding USD 83M


Clear Labs
2014 , Menlo Park (United States)
Provider of food analytics using human genome sequencing
Investors: GV, SGH Capital + 21 more
Last round: USD 40M, Series B, May 2020

Disclosed Funding USD 81M


Immunai
2018 , New York City (United States)
Developer of ML leveraged solutions catering to the immune system
Investors: Gefen Capital, Catalio Capital Management + 6 more
Last round: USD 60M, Series A, Feb 2021

Disclosed Funding USD 80M


Glympse Bio
2015 , Cambridge (United States)
Provider of noninvasive and predictive monitoring of multiple human diseases
Investors: Polaris Partners, Kiran Mazumdar Shaw + 17 more
Last round: USD 47M, Series B, Jun 2020

Disclosed Funding USD 79M


Lyndra
2015 , Cambridge (United States)
Drug Delivery company that develops oral drug delivery for once-a-week formulations
Investors: Bill & Melinda Gates Foundation, GF Securities + 14 more
Last round: USD 13M, Grant (prize money), Jul 2019

Disclosed Funding USD 78M


Aspen Neuroscience
2018 , La Jolla (United States)
Provider of genomic-based personalised pluripotent stem cell therapy
Investors: Alexandria, Sam Altman + 6 more
Last round: USD 70M, Series A, Apr 2020

Disclosed Funding USD 77M


Nautilus Biotechnology
2016 , San Carlos (United States)
Developer of proteomics platform for drug development
Investors: Bezos Expeditions, Defy + 5 more
Last round: USD 76M, Series B, May 2020

Disclosed Funding USD 76M


Mammoth
2017 , San Francisco (United States)
Developer of diagnostics using CRISPR technology
Investors: NFX, Verily + 21 more
Last round: Series B, Jan 2021

Disclosed Funding USD 76M


Healx
2014 , Cambridge (United Kingdom)
Therapeutic solutions for rare diseases using big data, genomics
Investors: Daniel Gutenberg, 3e Capital + 10 more
Last round: USD 56M, Series B, Oct 2019

Disclosed Funding USD 68M


Life Biosciences
2017 , Boston (United States)
Developer of therapies that control aging
Investors: Falcon Edge Capital, LeFrak + 2 more
Last round: USD 18M, Series B, Jun 2020

Disclosed Funding USD 68M


Frontier Medicines
2018 , San Francisco (United States)
Bioinformatics platform for drug development and chemoproteomics
Investors: Droia Ventures, MPM Capital + 5 more
Last round: USD 67M, Series A, Nov 2020

Disclosed Funding USD 67M


Phoremost
2015 , Cambridge (United Kingdom)
Developer of phenotypic screening platform to identify specific targets/pathways
Investors: Amadeus Capital, Cambridge Angels + 13 more
Last round: USD 46M, Series B, Mar 2021

Disclosed Funding USD 65M


MycoWorks
2013 , San Francisco (United States)
Developer of artificial leather using mycelium and agricultural byproducts
Investors: Novo Holdings, Natalie Portman + 15 more
Last round: USD 45M, Series B, Nov 2020

Disclosed Funding USD 62M


MOBILion Systems
2015 , Philadelphia (United States)
Manufacturer of mass spectroscopy instruments for clinical solutions
Investors: Agilent, aMoon + 7 more
Last round: USD 100K, Grant (prize money), Dec 2020

Disclosed Funding USD 54M


Checkerspot
2016 , Oakland (United States)
Novel materials for various applications using synthetic biology
Investors: Viking Global Investors, Builders VC + 10 more
Last round: USD 36M, Series B, May 2020

Disclosed Funding USD 54M


NuProbe
2016 , George Town (Cayman Islands)
Develops sensitive multiplex tool for QPCR
Investors: BioTrack Capital, Sequoia Capital + 6 more
Last round: USD 42M, Series B, Jan 2021

Disclosed Funding USD 53M


Bit bio
2016 , Cambridge (United Kingdom)
Developer of the new generation of cell therapies
Investors: BlueYard, Foresite Capital + 2 more
Last round: USD 42M, Series A, Jun 2020

Disclosed Funding USD 50M


Trace Genomics
2015 , San Francisco (United States)
Services for soil testing and disease prediction
Investors: Wheatsheaf Group, TERRA + 13 more
Last round: USD 17M, Series B, Jul 2020

Disclosed Funding USD 43M


ReCode Therapeutics
2016 , Dallas (United States)
Developer of proprietary tRNA-nano-particle therapeutics
Investors: Osage University Partners, Vida Ventures + 3 more
Last round: USD 80M, Series A, Mar 2020

Disclosed Funding USD 82M


Jasper Therapeutics
2017 , Menlo Park (United States)
Developer of immunological drugs that enable stem cell transplants and gene therapies
Investors: Alexandria, Qiming + 4 more
Last round: USD 14M, Series A, Jan 2020

Disclosed Funding USD 82M


Miroculus
2013 , Mountain View (United States)
Non-invasive microRNA detection platform for liquid biopsy of cancer
Investors: Mountain Partners, Kayyak + 10 more
Last round: USD 20M, Series A, Feb 2021

Disclosed Funding USD 48M


Skyhawk Therapeutics
2017 , Waltham (United States)
Developer of drug discovery platform for small molecules
Investors: Disney, Acks + 7 more
Last round: USD 40M, Series A, Jun 2018

Disclosed Funding USD 48M


CorneaGen
2017 , Seattle (United States)
Developer of tissues for corneal transplant
Investors: Flying L Partners, Petrichor + 1 more
Last round: USD 25M, Conventional Debt, Oct 2019

Disclosed Funding USD 44M


Evonetix
2015 , Saffron Walden (United Kingdom)
Developer of synthetic biology platform
Investors: Draper Esprit, Data Collective + 8 more
Last round: USD 30M, Series B, Mar 2020

Disclosed Funding USD 43M


Molecular Assemblies
2013 , San Diego (United States)
Provider of an enzymatic DNA synthesis product for researchers
Investors: iSelect Fund, Argonautic + 14 more
Last round: USD 24M, Series A, Apr 2021

Disclosed Funding USD 43M


OpenTrons
2014 , Brooklyn (United States)
Developer of a liquid handling robot for lab automation
Investors: Y Combinator, MBX Capital + 10 more
Last round: USD 21M, Series A, Aug 2020

Disclosed Funding USD 41M


Fluidic Analytics
2013 , Cambridge (United Kingdom)
Develops microfluidic-based tools for protein characterization
Investors: IQ Capital, Cambridge Innovation Capital + 6 more
Last round: USD 31M, Series C, Nov 2018

Disclosed Funding USD 40M


Medisix Therapeutics
2017 , Singapore
Developer of CAR-T therapies
Investors: Lightstone Ventures, Osage University Partners + 1 more
Last round: USD 20M, Series A, Oct 2019

Disclosed Funding USD 40M


ArunA Bio
2017 , Athens (United States)
Provider of stem cell tools for research
Investors: Eshelman Ventures, Evolution VC Partners + 2 more
Last round: USD 11M, Series B, Apr 2021

Disclosed Funding USD 33M


TearClear
2015 , Copley Township (United States)
Developing preservative-free topical ophthalmic drugs
Investors: Flying L Partners + 3 more
Last round: USD 22M, Series B, Aug 2020

Disclosed Funding USD 32M


Aspect Biosystems
2013 , Vancouver (Canada)
3D bioprinting platform technology capable of creating living human tissues for drug testing
Investors: Hedgewood, Pallasite Ventures + 14 more
Last round: USD 20M, Series A, Jan 2020

Disclosed Funding USD 30M


BRAINBox Solutions
2016 , Richmond (United States)
Provider of blood bio-marker for patient recovery
Investors: Tauber Family Foundation Inc, Genoa Ventures + 3 more
Last round: USD 23M, Series A, Dec 2020

Disclosed Funding USD 29M


Mimetas
2013 , Leiden (Netherlands)
Develops microfluidics-based organ-on-a-chip tissue models
Investors: Zeeuws Investment Fund, Merieux Equity Partners + 8 more
Last round: USD 21M, Series B, Apr 2018

Disclosed Funding USD 29M


Culture Biosciences
2016 , San Francisco (United States)
Developer of digital biomanufacturing platform
Investors: Y Combinator, Verily + 12 more
Last round: USD 22M, Series A, Mar 2020

Disclosed Funding USD 27M


Eligo Bioscience
2014 , Paris (France)
Developer of antimicrobial using CRISPR/Cas system
Investors: Seventure Partners, Agoranov + 1 more
Last round: USD 2M, Grant (prize money), Sep 2017

Disclosed Funding USD 22M


ARTMS
2013 , Vancouver (Canada)
Provider and developer of radioisotope technologies
Investors: Deerfield, GF Securities + 2 more
Last round: USD 300K, Grant (prize money), Feb 2021

Disclosed Funding USD 22M


Immunicom
2013 , San Diego (United States)
Developer of a immunotherapy device
Investors: CZV Capital, Oakdene Capital + 1 more
Last round: USD 2M, Series B, Oct 2019

Disclosed Funding USD 22M

CARDEA_Logo_IVORY_Thumb
Cardea Bio
2019 , San Diego (United States)
Developer of digital graphene biosensors using ML
Investors: Table Mountain Capital, 3E Bioventures Capital + 8 more
Last round: USD 7M, Series A, Jan 2021

Disclosed Funding USD 22M


TARA Biosystems
2014 , New York City (United States)
Human heart tissue models for drug discovery
Investors: Alexandria, New York Venture Partners + 15 more
Last round: USD 10M, Series A, Jun 2020

Disclosed Funding USD 21M


Syndesi Therapeutics
2018 , Louvain-la-neuve (Belgium)
Developer of small molecule for treating Alzheimer's disease
Investors: UCB, SRIW + 5 more
Last round: USD 4M, Grant (prize money), Mar 2019

Disclosed Funding USD 21M


Versantis
2015 , Zurich (Switzerland)
Drug developer for liver disease therapeutics and diagnostics
Investors: Occident Group, Esperante Ventures + 12 more
Last round: USD 16M, Series B, Sep 2019

Disclosed Funding USD 21M


Catalog Technologies
2016 , San Francisco (United States)
Developer of digital information storage system using synthetic DNA
Investors: Data Collective, The OS Fund + 23 more
Last round: USD 10M, Series A, Sep 2020

Disclosed Funding USD 21M


Magnetic Insight
2014 , Alameda (United States)
Provider of solutions for pre-clinical MRI imaging
Investors: StartX, SV Tech Ventures + 15 more
Last round: Grant (prize money), Sep 2019

Disclosed Funding USD 21M


Cellino Biotech
2017 , Cambridge (United States)
Developer of mature stem cells for clinical therapies
Investors: Humboldt, 8VC + 3 more
Last round: USD 16M, Seed, Feb 2021

Disclosed Funding USD 20M


Bionaut Labs
2015 , Los Angeles (United States)
Developer of miniature robots for surgery
Investors: Upfront Ventures, Bold Capital Partners + 3 more
Last round: USD 20M, Series B, Mar 2021

Disclosed Funding USD 20M


54gene
2019 , Lagos (Nigeria)
Developer of gene bank of African population for research and development
Investors: Aera VC, Y Combinator + 13 more
Last round: USD 15M, Series A, Apr 2020

Disclosed Funding USD 20M


Phylos Bioscience
2014 , Portland (United States)
Developer of cannabis breeding tools for agriculture & other health purposes
Investors: Entourage Effect Capital, Artemis Growth Partners + 2 more
Last round: USD 12M, Series C, Apr 2021

Disclosed Funding USD 19M


Ionpath
2014 , Menlo Park (United States)
Developer of an imaging platform for tissue biopsies
Investors: Genoa Ventures, Agile Angel + 6 more
Last round: USD 18M, Series B, Sep 2020

Disclosed Funding USD 18M


NanoView Biosciences
2015 , Boston (United States)
Provider of a nanotechnology based molecular diagnostic platform
Investors: America’s Seed Fund, Esco Ventures + 4 more
Last round: USD 6M, Series B, Dec 2020

Disclosed Funding USD 16M


twoXAR
2014 , Mountain View (United States)
Provider of data science-based drug discovery
Investors: StartX, The OS Fund + 3 more
Last round: USD 10M, Series A, Mar 2018

Disclosed Funding USD 14M


PathogenDX
2014 , Tucson (United States), Scottsdale (United States)
Provider of DNA-based pathogen testing kits
Investors: Arcadian Investment Partners, Altitude Investment Management + 7 more
Last round: Grant (prize money), Aug 2020

Disclosed Funding USD 12M


Bioskryb
2018 , Durham (United States)
Developer of a genome sequencing and amplification system
Investors: Anzu Partners, Wilson Sonsini Goodrich & Rosati
Last round: USD 12M, Seed, Jan 2020

Disclosed Funding USD 12M
Written by Tracxn Technologies
press release

But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system.